Prosecution Insights
Last updated: November 04, 2026

Ferric Contrast Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Ferric Contrast Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a distinct examiner, SCHLIENTZ, LEAH H, who is the busiest examiner for the portfolio with 1 pending action. Prosecution is concentrated in a distinct art unit. The narrow focus of this portfolio suggests a highly specific technical scope within the biotechnology sector. Practitioners should note that the entire pending workload rests with a single examiner, making individual examiner tendencies critical for overall strategy.

The presence of a pending office action indicates a streamlined prosecution environment. Because the portfolio is limited to a single distinct examiner and a single distinct art unit, there is no internal baseline for comparing examiner behavior or art unit efficiency within the company's own data. Success for Ferric Contrast Inc. depends on navigating the specific requirements of SCHLIENTZ, LEAH H. This concentration under a single point of review simplifies administrative tracking but increases the impact of any single procedural hurdle.

In the Biotechnology & Pharmaceuticals field, where examination can be highly technical, having a distinct art unit involved suggests a consistent application of subject matter standards. However, the reliance on a distinct examiner means that the company's patent trajectory is currently subject to a single perspective. Practitioners should focus on the historical allowance rates and common rejection types associated with the specific examiner to optimize their response strategy for the pending office action.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SCHLIENTZ, LEAH H 1 41.6% +38.4%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18551458 IRON(III) MACROCYCLIC COMPLEXES WITH MIXED HYROXYL PENDANTS AS MRI CONTRAST AGENTS SCHLIENTZ, LEAH H —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18551458 IRON(III) MACROCYCLIC COMPLEXES WITH MIXED HYROXYL PENDANTS AS MRI CONTRAST AGENTS SCHLIENTZ, LEAH H —

Top Art Units

Art UnitApps
1618 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18551458 IRON(III) MACROCYCLIC COMPLEXES WITH MIXED HYROXYL PENDANTS AS MRI CONTRAST AGENTS SCHLIENTZ, LEAH H 1618 §102§103§112 Non-Final OA — Pending Sep 20, 2023

Managing Ferric Contrast Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Ferric Contrast Inc. have?

Ferric Contrast Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Ferric Contrast Inc. applications?

Leah H Schlientz has the most, with 1 of Ferric Contrast Inc.'s pending office actions.

What technology area are Ferric Contrast Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month